Literature DB >> 4110897

Simultaneous measurement of thyroxine and triiodothyronine peripheral turnover kinetics in man.

J T Nicoloff, J C Low, J H Dussault, D A Fisher.   

Abstract

Serum triiodothyronine (T(3)) kinetics in man have been difficult to define presumably due to the interference of iodoproteins generated during the peripheral metabolism of T(3). The use, in the present study, of an anion-column chromatographic method for separation of serum T(3) as well as thyroxine (T(4)) from these iodoproteins has overcome this technical handicap. Simultaneous measurement of serum (125)I-T(3) and (131)I-T(4) kinetics were performed in 31 subjects from the clinical categories of euthyroid, primary hypothyroid, thyrotoxic and posttreatment hypothyroid Graves' disease, factitial thyrotoxic, and idiopathically high and low thyroxinebinding globulin states. The normal mean T(3) fractional turnover rate (kT(3)) was 0.68 (half-life = 1.0 days), increased in toxic Graves' disease patients to 1.10 (half-life = 0.63 days), and decreased in primary hypothyroid patients to 0.50 (half-life = 1.38 days). The mean T(3) equilibration time averaged 22 hr except in hypothyroid and high thyroxine-binding globulin (TBG) patients where the equilibration period was delayed by 10 hr. The mean T(3) distribution space in normal subjects was 38.4 liters. This was reduced in subjects with high TBG levels (26 liters) and increased in patients with low TBG and in all hyperthyroid states (53-55 liters). The normal serum T(3) concentration was estimated by radioimmunoassay to be 0.106 mug/100 ml. Combined with the mean T(3) clearance value of 26.1 liters/day, the calculated T(3) production rate was 27.6 mug/day. The mean T(3) production rate increased to 201 mug/day in thyrotoxic Graves' disease patients and was reduced to 7.6 mug/day in primary hypothyroid subjects. T(3) production rate was normal in subjects with altered TBG states. The ratio of T(3) to T(4) production rate in normal subjects was 0.31 and was unchanged in patients with altered TBG values. This ratio was increased in all Graves' disease patients with the highest value being 0.81 in the posttreatment hypothyroid Graves' disease group. This apparent preferential production of T(3) may have been responsible for the retention of rapid turnover kinetics for T(3) and T(4) observed in treated Graves' disease patients. The finding that factitial thyrotoxic patients also displayed similar rapid T(3) and T(4) turnover kinetics indicates that these alterations are not a unique feature of Graves' disease per se. When comparing the peripheral turnover values for T(3) and T(4) in man, it is apparent that alterations in metabolic status and serum TBG concentration influence both hormones in a parallel manner; however, changes in metabolic status seem to have a greater influence on T(3) kinetics while alterations in TBG concentrations have a greater effect on T(4). These observations probably relate to the differences in TBG binding affinity and peripheral tissue distribution of these two hormones.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4110897      PMCID: PMC302152          DOI: 10.1172/JCI106835

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  26 in total

1.  Disappearance of I-131-triiodo-thyronine from the plasma in the presence of fever.

Authors:  J G WISWELL; V CORONHO
Journal:  J Clin Endocrinol Metab       Date:  1962-06       Impact factor: 5.958

2.  Studies of thyroid function and the peripheral metabolism of I 131-labeled thyroxine in patients with treated Graves disease.

Authors:  S H INGBAR; N FREINKEL
Journal:  J Clin Invest       Date:  1958-11       Impact factor: 14.808

3.  Disappearance from serum of I131-labeled l-thyroxine and l-triiodothyronine in euthyroid subjects.

Authors:  K STERLING; J C LASHOF; E B MAN
Journal:  J Clin Invest       Date:  1954-07       Impact factor: 14.808

4.  CLINICAL AND PHYSIOLOGICAL OBSERVATIONS IN A PATIENT WITH AN IDIOPATHIC DECREASE IN THE THYROXINE-BINDING GLOBULIN OF PLASMA.

Authors:  S H Ingbar
Journal:  J Clin Invest       Date:  1961-11       Impact factor: 14.808

5.  Estimation of thyroxine distribution in man.

Authors:  J T Nicoloff; J T Dowling
Journal:  J Clin Invest       Date:  1968-01       Impact factor: 14.808

6.  Endemic goiter in Greece: thyroid hormone kinetics.

Authors:  D A Koutras; M Berman; J Sfontouris; G A Rigopoulos; A S Koukoulommati; B Malamos
Journal:  J Clin Endocrinol Metab       Date:  1970-04       Impact factor: 5.958

7.  The distribution kinetics of triiodothyronine: studies of euthyroid subjects with decreased plasma thyroxine-binding globulin and patients with Graves' disease.

Authors:  R R Cavalieri; M Steinberg; G L Searle
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

8.  The peripheral metabolism of triiodothyronine in normal subjects and in patients with hyperthyroidism.

Authors:  K A Woeber; R J Sobel; S H Ingbar; K Sterling
Journal:  J Clin Invest       Date:  1970-04       Impact factor: 14.808

9.  Hypoxic ventilatory drive in normal man.

Authors:  J V Weil; E Byrne-Quinn; I E Sodal; W O Friesen; B Underhill; G F Filley; R F Grover
Journal:  J Clin Invest       Date:  1970-06       Impact factor: 14.808

10.  Thyroid hormone transport in the serum of patients with thyrotoxic Graves' disease before and after treatment.

Authors:  L E Braverman; A E Foster; S H Ingbar
Journal:  J Clin Invest       Date:  1968-06       Impact factor: 14.808

View more
  36 in total

1.  The radioimmunoassay of triiodothyronine and its clinical application.

Authors:  C J Eastman; J M Corcoran; R P Ekins; E S Williams; J D Nabarro
Journal:  J Clin Pathol       Date:  1975-03       Impact factor: 3.411

2.  Estimation of thyroxine and triiodothyronine distribution and of the conversion rate of thyroxine to triiodothyronine in man.

Authors:  M Inada; K Kasagi; S Kurata; Y Kazama; H Takayama; K Torizuka; M Fukase; T Soma
Journal:  J Clin Invest       Date:  1975-06       Impact factor: 14.808

3.  Pharmacokinetics of L-Triiodothyronine in Patients Undergoing Thyroid Hormone Therapy Withdrawal.

Authors:  Benjamin Van Tassell; George F Wohlford; Joyce D Linderman; Sheila Smith; Sahzene Yavuz; Frank Pucino; Francesco S Celi
Journal:  Thyroid       Date:  2019-09-12       Impact factor: 6.568

Review 4.  Multigenic control of thyroid hormone functions in the nervous system.

Authors:  Jacques Nunez; Francesco S Celi; Lily Ng; Douglas Forrest
Journal:  Mol Cell Endocrinol       Date:  2008-03-25       Impact factor: 4.102

5.  Guidelines for the treatment of hypothyroidism: prepared by the american thyroid association task force on thyroid hormone replacement.

Authors:  Jacqueline Jonklaas; Antonio C Bianco; Andrew J Bauer; Kenneth D Burman; Anne R Cappola; Francesco S Celi; David S Cooper; Brian W Kim; Robin P Peeters; M Sara Rosenthal; Anna M Sawka
Journal:  Thyroid       Date:  2014-12       Impact factor: 6.568

6.  An assessment of daily production and significance of thyroidal secretion of 3, 3', 5'-triiodothyronine (reverse T3) in man.

Authors:  I J Chopra
Journal:  J Clin Invest       Date:  1976-07       Impact factor: 14.808

7.  Substitution of liothyronine at a 1:5 ratio for a portion of levothyroxine: effect on fatigue, symptoms of depression, and working memory versus treatment with levothyroxine alone.

Authors:  Tom Rodriguez; Victor R Lavis; Janet C Meininger; Asha S Kapadia; Linda F Stafford
Journal:  Endocr Pract       Date:  2005 Jul-Aug       Impact factor: 3.443

8.  Stable Isotope Pharmacokinetic Studies Provide Insight into Effects of Age, Sex, and Weight on Levothyroxine Metabolism.

Authors:  Islam R Younis; Mariam A Ahmed; Kenneth D Burman; Offie P Soldin; Jacqueline Jonklaas
Journal:  Thyroid       Date:  2018-01-02       Impact factor: 6.568

9.  3,3'-Diiodothyronine production, a major pathway of peripheral iodothyronine metabolism in man.

Authors:  L A Gavin; M E Hammond; J N Castle; R R Cavalieri
Journal:  J Clin Invest       Date:  1978-05       Impact factor: 14.808

10.  Triiodothyronine and thyroxine in hyperthyroidism. Comparison of the acute changes during therapy with antithyroid agents.

Authors:  J Abuid; P R Larsen
Journal:  J Clin Invest       Date:  1974-07       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.